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Abstract Cystic fibrosis (CF) is the most common
hereditary lung disease in the Caucasian population, char-
acterized by viscous bronchial secretion, consecutive
defective mucociliary clearance, and unavoidable colo-
nization with microorganisms. Besides Pseudomonas
aeruginosa, Staphylococcus aureus is the most common
bacterial species colonizing the CF respiratory tract. Under
antibiotic pressure S. aureus is able to switch to small
colony variants (SCV). These small colony variants can
invade epithelial cells, overcome antibiotic therapy inside
the cells and can be the starting point for extracellular
recolonization. The aim of the present study was the iso-
lation and characterization of S. aureus small colony
variants from Austrian cystic fibrosis patients. Samples
collected from 147 patients were screened for the presence
of S. aureus wild-type and small colony variants. Antibi-
otic susceptibility testing and determination of the small
colony variants causing auxotrophism were performed.
Wild-type isolates were assigned to corresponding small
colony variants with spa typing. In total, 17 different small
colony variant isolates and 12 corresponding wild-type
isolates were obtained. 13 isolates were determined thy-
midine auxotroph, 2 isolates were auxotroph for hemin,
and none of the tested isolates was auxotroph for both,
respectively. The presence of SCVs is directly related to a
poor clinical outcome, therefore a monitoring of SCV
prevalence is recommended. This study revealed rather low
SCV ratios in CF patients compared to other countries.
Introduction
Cystic fibrosis (CF) is the most common hereditary lung
disease in the white (Caucasian) population [1, 2, 13, 19,
30]. CF is caused by mutations in the gene that encodes the
cystic fibrosis transmembrane conductance regulator
(CFTR) protein [9, 23]. Abnormal CF transmembrane
conductance regulator function initiates a pathophysiologic
cascade of chronic airway inflammation and suppurative
infection resulting in progressive pulmonary insufficiency.
Ultimately, 95 % of patients with CF succumb to respira-
tory failure.
In the last years, studies revealed an association between
Pseudomonas aeruginosa (P. aeruginosa) and CF lung
function decline [12, 18], so the microbial researches and
therapy strategies focused on P. aeruginosa. However,
recent studies describe an increase of Staphylococcus
aureus (S. aureus) prevalence in CF, both methicillin-
susceptible and methicillin-resistant (MRSA) strains [14].
Latest studies on children with CF noted similar inflam-
mation and lung function decline during infection with S.
aureus compared with P. aeruginosa [15, 28, 42].
S. aureus is thought to persist in CF patients over years
and adapts to this environment. One occurrence of adaption
is the so-called small colony variant (SCV) phenotype.
This phenotype has been reported from various bacterial
and fungal species and the transformation to a SCV phe-
notype is triggered by several stress factors [8, 20]. The
genetic background of the SCV phenotypes is based on
mutations, that lead to auxotrophy in metabolic pathways.
Three major types of S. aureus SCVs have been found in
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CF isolates, namely strains that are auxotroph for thymi-
dine, menadione, or hemin [10, 41].
The switching to the SCV phenotype enables S. aureus
to hide inside host cells and to escape from immune
responses. The reduced doubling speed and alteration of
pathways of SCVs also lead to an increased antibiotic
resistance [3, 16, 44]. The intracellular activity of SCV
phenotypes is additionally characterized by a lack of typ-
ical S. aureus pathogenic functions. The only persistence of
SCVs does not seem to be a problem for the patient, but the
instability of most SCVs bears the risk of reconversion to
the fast growing and virulent wild type [25, 39]. So SCV
strains have significant clinical importance and in some
cases they can even persist for up to 50 years in the patient
[31].
S. aureus SCVs are difficult to detect, as they generally
grow slowly and often need several days to become visible
on agar plates. They have altered drug-resistance profiles,
such as an increased resistance to aminoglycosides [33,
36]. Currently, most clinical laboratories are unable to
detect S. aureus SCVs, as adapted culture methods are not
implemented in routine diagnostics [3, 44]. Results of
susceptibility testing by disk diffusion or automated
methods are often invalid or even not possible. The colo-
nies are too small to be seen on agar plates or to be detected
by automated systems [24].
Patients at risk of SCV S. aureus infection are patients
with long-term antibiotic therapy [29], so besides from
patients with CF also patients with endocarditis, pneumo-
nia, soft tissue infections, osteomyelitis, and severe bac-
teraemia. The frequency of SCV recovery from clinical
specimens ranges from 1 to 30 % in CF patients [33].
The aim of the present study was a first epidemiolog-
ical look for SCVs in the airways of CF patients in
Southeast Austria. All isolates were characterized by spa
typing. Additionally their antibiotic susceptibility and the
underlying auxotrophism were tested, in order to provide
a characterization of CF SCV S. aureus strains in our
region.
Materials and Methods
Clinical isolates were obtained at the CF center at the
Respiratory and Allergic Disease Division, Department of
Paediatrics and Adolescent Medicine (Medical University
of Graz), between January 2011 and December 2013. All
CF patients of the center in Graz (ambulant and stationary
patients, including all CF patients under treatment in
Southeast Austria) are microbiologically screened at least
four times per year. All S. aureus isolates included in this
study were investigated at the CF Laboratory at the
Institute of Hygiene, Microbiology and Environmental
Medicine (IHMEM, Medical University of Graz).
Collection of Bacterial Isolates
Sputum samples and mucoid BAL fluid samples were
immediately processed with Sputasol (Oxoid) containing
the sputum liquefying agent dithiothreitol in a weight ratio
of 1:2, incubated at room temperature for 10–15 min and
vortexed. This was followed by a serial dilution up to a 105
dilution. 100 ll of the liquefied and diluted suspensions
were plated onto TSA (Tryptocase-Soja-Agar, bioMe´rieux,
Austria), Mac Conkey-Agar (bioMe´rieux, Austria), and
SAID (Staphylococcus aueus identification-Agar, bioMe´r-
ieux, Austria). 50 ll of the liquefied origin were plated on
Chocolate-Agar (bioMe´rieux, Austria), BCSA-Agar (bio-
Me´rieux, Austria), Schaedler-Agar (bioMe´rieux, Austria),
and Meropenem and Polymyxin-Agar (IHMEM, Medical
University Graz). All agar plates were incubated at 35 C
for 72–120 h and up to 9 days at room temperature. The
first screening for SCV S. aureus was carried out after 72 h.
On TSA and blood-agar, non-hemolytic, non-pigmented,
small and fried egg colonies were suspected to be S. aureus
SCVs, on SAID all colonies were suspicious to be S.
aureus SCVs. All conspicuous colonies were inoculated on
blood and Schaedler-Agar [21]. If the colonies were nor-
mal-sized hemolytic and pigmented on Schaedler-Agar and
not on blood-agar, they were considered to be S. aureus
SCVs. These isolates were tested for species identification
by MALDI-TOF MS AximaTM Assurance (Shimadzu,
Japan). For this purpose, one colony of each isolate was
directly spotted on the FlexiMass MALDI target plate. For
automatic measurement and identification the SAR-
AMISTM (spectral archived microbial identification sys-
tem) database application from bioMe´rieux was applied.
Isolation of all other bacterial species was done as descri-
bed previously [26].
Spa Typing
Spa typing is based on sequencing the polymorphic X-re-
gion of the protein A gene (spa). This is a well-established
technique and the results can be compared with databases.
The determined spa types can be assigned to distinct
groups with known origin and characteristics [10].
Detection of mecA Gene
To confirm MRSA genotype, the presence of mecA was
analyzed in all isolates with the BD MAXTM System
(Beckton Dickinson Austria, Vienna), using the ‘‘BD MAX
MRSA assay’’ according to the manufacturer’s
instructions.
L. Masoud-Landgraf et al.: Analysis and Characterization of Staphylococcus aureus Small Colony… 607
123
Auxotrophism Test
SCV auxotrophism was tested using agar disk diffusion test
according to Maduka-Ezeh et al. on Mueller–Hinton agar for
thymidine, hemin, and menadione [37]. To identify poten-
tially double auxotrophic strains, the agar plates were also
loadedwith all three test substrates additionally [4, 32, 35, 38].
Determination of Antibiotic Resistance
Antibiotics tested were penicillin, oxacillin, gentamicin, ery-
thromycin, clindamycin, ciprofloxacin, tetracycline, rifampi-
cin, fusidic acid, vancomycin, linezolid, and mupirocin.
Resistance testing was performed as recommended by the
EuropeanCommittee onAntimicrobial Susceptibility Testing
(EUCAST, http://www.eucast.org/clinical_breakpoints/).
For the normal S. aureus strains, determination of the
minimal inhibitory concentration (MIC) was performed by
using VITEK-2 (bioMe´rieux, Solna, Sweden) and disk
diffusion method, and by E-test (bioMe´rieux, Solna, Swe-
den). For the determination of the antimicrobial suscepti-
bilities of the SCV S. aureus strains resistance was tested
on brain–heart infusion (BHI) agar [21].
Results
Collection of Bacterial Isolates
Samples originated from 147 patients (75 male, 72 female).
The patients’ age ranged from 10 months to 56 years, with a
median age of 19 years. Samples included sputa (n = 1452),
nasal swabs (n = 518), throat swabs (n = 466), and bron-
choalveolar lavage (BAL) fluids (n = 58). In total, 1399 S.
aureus isolates could be recovered in 127 patients (86.4 %),
two of them were tested phenotypically and genotypically
(mecA gene) positive for MRSA. 12 patients harbored SCV
S. aureus isolates including the twoMRSA positive patients.
So, 8.2 % of the CF patients and 9.4 % of S. aureus positive
CF patients were positive for S. aureus SCVs, respectively.
74 S. aureus (27 SCV and 47 wild types) could be isolated
from the 12 SCV positive patients during the study period.
Only eight (66.7 %) of the patients with SCV strains
were co-colonized with P. aeruginosa, whereas 95 of 127
(74.8 %) of S. aureus positive patients were also positive
for P. aeruginosa. None of them was co-colonized with
Haemophilus influenzae and three (18.8 %) of them were
positive for Stenotrophomonas maltophilia.
Spa Typing
In total, 21 different spa types could be detected. SCV S.
aureus revealed 13 spa types; 10 of these spa types could
also be identified in wild-type S. aureus isolates from the
same patient (Table 1). Three SCV spa types could not be
assigned to a wild-type strain and 8 spa types were only
present in wild type (data not shown). Only two spa types
(t002 and t085) were present in more than one patient
(Table 1).
S. aureus SCV were classified as identical if they had
the same spa type and the same auxotrophism. 10 out of 12
CF patients (patients 1, 2, 3, 4, 6, 7, 8, 10, 11, and 12)
harbored one SCV isolate. From two patients (patients 5
and 9) SCV S. aureus with different wild-type strains could
be isolated. The isolated strain of patient 9 was the only
one that had developed different SCV phenotypes
(Table 1).
Auxotrophism
Thirteen of the tested 17 isolates showed thymidine aux-
otrophism, and two times hemin dependence was recov-
ered; menadione auxotrophism could not be linked to any
isolate. Two isolates showed no response to the substrates
and the auxotrophism could therefore not be addressed
(Table 1). In contrast to the others, the t085 isolates of
patient 9 showed SCV phenotype differentiation into thy-
midine, hemin, and a non-assignable type of auxotrophism.
This spa type was also the only one that had developed
different SCV phenotypes.
Antibiotic Susceptibility of SCVs
Antibiotic susceptibility was determined for 17 strains. The
highest resistance rate was observed for penicillin/ampi-
cillin with 14 isolates (82.4 %). Resistance against ery-
thromycin/clindamycin was present in nine isolates
(52.9 %). On the basis of MIC testing with E-test, two
isolates (11.7 %) were oxacillin resistant and therefore
MRSA. All tested isolates were susceptible to tetracyclin,
fusidic acid, linezolid, vancomycin, and mupirocin
(Table 2).
Discussion
Over a period of long-term infection, S. aureus may
undergo extensive adaptation to the lung environment in
CF patients [17]. One mentionable effect of this adaptation
is the transition toward a slow-growing low virulence state,
the small colony variant. SCVs mutants enable advantages
under chronic infection conditions. For example, SCVs
have the ability to survive intracellularly, where they are
protected against phagocytosis and from extracellular
antimicrobial agents. So, they overcome different envi-
ronmental pressures (antibiotic treatment or bacterial
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competitors). The relation between the presence of SCVs
and a poor clinical outcome has already been reported in
several studies, with patients harboring SCV variants
having lower blood oxygen levels and a significantly lower
FEV1 score [5, 34].
Long-term treatment with trimethoprim/sulfamethoxa-
zole (SXT) or aminoglycosides favors the emergence of
thymidine-dependent SCVs in CF patients [7, 43]. This is
in concordance with our data, as the patients in our study
had previously been treated with SXT.
The prevalence of thymidine-dependent SCV strains in
CF patients has already been described [6, 11, 22]. We also
found a majority of thymidine-dependent strains, whereas
not a single menadione-dependent strain could be detected.
The reason for the absence of menadione auxotroph SCVs
might be the extremely slow growth of the menadione
auxotroph SCVs which could have been overgrown by
faster growing variants.
Recent publications e.g., Melter et al. reported that SCV
variants are much more resistant to antibiotics than the
non-SCV S. aureus isolates [29]. In contrast, we could not
find any difference in the resistance rates between wild-
type S. aureus strains and SCV S. aureus strains.
Twelve patients were SCV positive, so the SCV S.
aureus prevalence was 8.1 %, lower than previously
reported from CF studies in other countries [45]. The
Table 1 Antibiotic resistance pattern, type of auxotrophism, and spa types of the SCV isolates of 12 patients
SCV Pat Nr SCV isolation date Auxotrophism Spa-
type
Resistance Isolation date of the paired S. aureus strain
1 1 28.02.2013 Thymidine t12308 P, AM, E, CC, GM 28.05.2010
15.12.2010
05.11.2013
2 2 07.02.2013 Thymidine t209 P, AM, E, CC 28.08.2010
07.12.2011
29.06.2012
3 3 25.02.2013 Thymidine t012 P, AM Paired strain could not be found
4 4 17.10.2013 Thymidine t732 E, CC 04.10.2010
5 5 07.11.2013 Thymidine t002 OXA, P, AM, E, CC, GM, NN 28.11.2012
07.11.2013




7 6 08.07.2013 Thymidine t8012 P, AM, E, CC 20.07.2010
28.10.2013
8 7 11.09.2012 Thymidine t004 GM 25.07.2011
30.07.2013
9 8 11.04.2013 Thymidine t085 P, AM Paired strain could not be found
10 9 08.08.2012 Thymidine t085 P, AM 09.05.2012
11 9 16.03.2013 Not known t085
12 9 15.05.2013 Hemin t085 P, AM, GM
13 9 20.09.2011 Thymidine t645 P, AM, E, CC, GM Paired strain could not be found
14 9 13.02.2013 Thymidine t015 P, AM, CIP 25.05.2010
25.01.2011
15 10 25.06.2013 Not known t2249 P, AM, E, CC, GM 02.11.2010
17.10.2012
16.07.2013
16 11 05.09.2013 Hemin t002 P, AM, E, CC 10.08.2010
17 12 12.09.2012 Thymidine t9847 P, AM, E, CC 12.07.2010
06.11.2012
20.11.2013
OXA oxacillin, P penicillin, AM ampicillin, E erythromycin, CC clindamycin, GM gentamicin, NN tobramycin, CIP ciprofloxacin, RIF
rifampicin
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prevalence of MRSA also is very low in our center. Oxa-
cillin resistance was found in 11.7 % of the SCVs. This
could be related to local infection control and the low
incidence of nosocomial S. aureus acquisition in our CF
center; multiple antibiotic-resistant S. aureus SCVs was not
a common occurrence in this study [27, 43].
The suggested inductive effect on S. aureus SCV via P.
aeruginosa co-infection could not be verified in our study
but this might be related to the relatively low number of S.
aureus SCV isolates [40, 43].
In conclusion, this first report on S. aureus SCVs from
an Austrian CF center revealed a high number of S. aureus
positive CF patients but rather low SCV prevalence. A tight
cooperation between clinicians and microbiological labo-
ratory is essential for a successful management of the
underestimated SCV challenge.
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